IceCure Medical Ltd (ICCM) Stock Forecast
ICCM analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.67 / 5 from 3 analysts
- Price target
- $22.67 average of analyst targets
- Upside to target
- +2,038.4% from the latest close
- Next earnings
- November 18, 2026 EPS estimate $-0.83
- 52-week range
- $1.04 – $25.69
ICCM analyst ratings
3 analystsNumber of analysts at each rating.
ICCM price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
ICCM earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.83 | −$0.83 | −$0.83 | −$1.80 | +53.9% | 1 |
| Current fiscal year (2026) | −$4.61 | −$4.61 | −$4.61 | −$7.20 | +36.0% | 1 |
| Next fiscal year (2027) | −$3.44 | −$3.71 | −$3.00 | −$5.57 | +38.2% | 3 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
ICCM revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $876,500 | $850,000 | $903,000 | +3.1% | 2 |
| Current fiscal year (2026) | $4.3M | $4.2M | $4.4M | +27.1% | 2 |
| Next fiscal year (2027) | $8.8M | $6.9M | $12.5M | +105.0% | 3 |
ICCM EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
ICCM revenue: reported and forecast
ICCM EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | −$0.88 | −$0.88 | −$0.83 | −$0.83 | −$0.83 | −5.7% | 0 up · 1 down |
| Current fiscal year (2026) | −$4.75 | −$4.75 | −$4.61 | −$4.61 | −$4.61 | −3.0% | 0 up · 1 down |
| Next fiscal year (2027) | −$3.87 | −$3.87 | −$3.44 | −$3.44 | −$3.44 | −11.2% | 1 up · 1 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
ICCM earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; ICCM beat in 7 of 12.
What analysts expect from ICCM
3 analysts cover IceCure Medical; their consensus rating is strong buy (4.67 on a 1–5 scale, where 5 is a strong buy). The average price target is $22.67, 2,038.4% above the latest close of $1.06. Analysts expect earnings of −$4.61 per share for 2026, +36.0% from a year earlier. For 2027 the average estimate is −$3.44 per share on revenue of $8.8 million. IceCure Medical beat the EPS estimate in 7 of the last 12 quarters.
Related: ICCM income statement, ICCM key metrics, ICCM chart. See the ICCM stock overview for the latest quote and news.
ICCM forecast FAQ
What is IceCure Medical's price target?
The average analyst price target for IceCure Medical is $22.67, 2,038.4% above the latest close of $1.06.
Is IceCure Medical a buy, hold or sell?
Of 3 analysts covering IceCure Medical, 2 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is IceCure Medical's EPS forecast?
Analysts forecast −$4.61 per share for 2026 (range −$4.61 to −$4.61); for 2027 the estimate is −$3.44.
What is IceCure Medical's revenue forecast?
The average revenue estimate for 2026 is $4.3 million, growth of 27.1%; for 2027 it is $8.8 million.
When does IceCure Medical report earnings?
IceCure Medical is expected to report results for the quarter ending September 30, 2026 on November 18, 2026 before the market opens; the EPS estimate is $-0.83.
Does IceCure Medical usually beat earnings estimates?
IceCure Medical reported EPS at or above the analyst estimate in 7 of the last 12 quarters.